NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RCMac who wrote (294)	1/31/1999 1:39:00 PM
From: RCMac	of 613

Another perspective on CORR: Message 7578160 Excerpts: "growth in overall market [for anti-clotting agents] should slow in 1999 with total CNTO sales of $450 million or so, up 25% or so from $360 million reported sales in 1997. CORR/MRK will likely take $50-75 million each leading to a bullish case market size of $600 million (75% CNTO, 13% MRK and 12% CORR - I have to assume MRK will hold slight lead). On a volume basis, assuming 1.5x higher Reo pricing, CNTO would have 67% share to 17% and 16% shares for MRK and CORR.." "CORR will likely do $70 million end-user sales in 1999. This should grow to $150-200 million by 2001. Ramp is slower than expected, but from a small base, this will ultimately be good for CORR." My horseback guess -- and he's looked at this in greater detail than I have -- is that he underestimates CORR's likely market share and overestimates CNTO's, but as a CORR shareholder I'll be happy even if he's exactly right. Notably, the author owns both CNTO and CORR. -- RCM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next